APIM Therapeutics

APIM Therapeutics is a Norwegian biotech company pioneering a novel approach to cancer therapy by targeting the proliferating cell nuclear antigen (PCNA) and its interaction with the AlkB homologue 2 PCNA interacting motif (APIM). Its lead clinical asset, ATX-101, is a first-in-class peptide that has progressed to Phase Ib trials in ovarian cancer and Phase II trials in sarcoma, aiming to overcome treatment resistance. The company is building a pipeline of peptide drugs focused on disrupting cancer cell survival mechanisms under therapeutic stress. Leveraging its academic roots from NTNU, APIM seeks to develop both single-agent and combination therapies for unmet needs in oncology.

Platform based on cell-penetrating peptides that mimic the APIM motif to inhibit interactions between PCNA and stress-response proteins, disrupting cancer cell survival under therapy-induced stress.

Competes in the broad and competitive oncology resistance space, which includes companies targeting DNA damage repair (e.g., PARP inhibitors), epigenetics, and other survival pathways. Differentiation hinges on the uniqueness of the PCNA-APIM axis as a target. Other peptide therapeutic companies also pose platform competition.